On June 4, 2020 Protagonist Therapeutics, Inc. (Nasdaq:PTGX) reported that the company will present data from its Phase 2 trial of PTG-300 for the treatment of beta-thalassemia at the 25th European Hematology Association (EHA) (Free EHA Whitepaper) Annual Congress, which will take place in a virtual format June 11-14, 2020 (Press release, Protagonist, JUN 4, 2020, View Source [SID1234560858]). Details of the oral presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Title: A hepcidin mimetic, PTG-300, demonstrates pharmacodynamic effects indicating reduced iron availability in transfusion-dependent beta-thalassemia subjects
Session: New therapeutic approaches for thalassemia
Abstract: S298
Date and Time: Available on the on-demand Virtual Congress platform on Friday, June 12, 2020, at 8:30 a.m. CEST